Guggenheim Reiterates Buy as Medicines Co. (MDCO) Prepares Phase 2 Data

August 15, 2016 7:26 AM EDT
Get Alerts MDCO Hot Sheet
Price: $36.50 -0.03%

Rating Summary:
    14 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade MDCO Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Guggenheim reiterated a Buy rating and $55.00 price target on The Medicines Company (NASDAQ: MDCO) as the company prepares to publish its 3-month and some 6-month Phase 2 data for its PCSK9 next month.

Analyst Louise Chen commented, "MDCO could publish 3-month and some 6-month Phase 2 data for its PCSK9 next month. The company expects to have most, if not all, of the 3-month data, and some of the 6-month data by September. Given the interest in PCKS9s, MDCO plans to publish a press release with top-line data as soon as possible, and provide more details at a medical conference. If the Phase 2 PCSK9 data for MDCO and outcomes data are both positive, we would expect MDCO's stock to trade toward our $55 PT. Based on our diligence, a 20%-30% reduction in heart attacks/death may be enough to increase uptake of this drug class."

For an analyst ratings summary and ratings history on The Medicines Company click here. For more ratings news on The Medicines Company click here.

Shares of The Medicines Company closed at $37.01 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Louise Chen, Guggenheim

Add Your Comment